Promising gene therapies pose million-dollar conundrum
Economists, investors and medical insurers can’t figure out how to pay for cutting-edge drugs.
Drugs that act by modifying a patient’s genes are close to approval in the United States, and one is already available in Europe. The developments mark a triumph for the field of gene therapy, onceconsidered controversial.
Ten years on
Induced pluripotent stem cells were supposed to herald a medical revolution. But ten years after their discovery, they are transforming biological research instead.